ADORA2B

Across TCGA pan-cancer cohorts, ADORA2B Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated ADORA2B data layer compared with 27 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher ADORA2B Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ADORA2B expression acts as an unfavorable survival marker.

BLCA, UCEC, and SKCM are the cancer types where ADORA2B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	All	0.089	0.720	<.001	48	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
SKCM	DFS	Median	All	0.181	0.613	.010	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

ADORA2B–BLCA (OS)

Open the BLCA breakdown →